期刊
AMERICAN JOURNAL OF TRANSPLANTATION
卷 7, 期 2, 页码 402-407出版社
WILEY
DOI: 10.1111/j.1600-6143.2006.01632.x
关键词
IVIG; kidney transplantation; memory B cells; plasma cells; rabbit antithymocyte globulin; rituximab
Rituximab, intravenous immunoglobulin (IVIG) and rabbit antithymocyte globulin (rATG) all have been suggested to have an effect on antibody producing cells, however, supporting data are lacking. To assess the impact of these agents on splenic B-cell populations in vivo, we retrospectively examined 25 spleens removed from patients treated with these agents as part of desensitization protocols in either ABO incompatible or positive crossmatch living donor kidney transplantation. These were compared to control (CTL) spleens removed for trauma. CTLs and spleens removed at transplant after multiple pretransplant plasmaphereses (PP) plus low-dose IVIG showed similar large numbers of naive B cells (CD20(+) and CD79(+)), plasma cells (CD138(+)) and memory B cells (CD27(+) cells). Adding rituximab to this PP/IVIG regimen reduced the number naive B cells, but had no effect on memory or plasma cells. Combination treatment (PP/IVIG, rituximab and rATG) showed a trend toward the reduction of CD27(+) cells, but again plasma cells were unchanged. We conclude that none of these protocols reduces splenic plasma cells in vivo. PP/low-dose IVIG does not alter splenic B cells, but the addition of rituximab decreases mature B cells. Memory B cells may be affected by combination therapy including rATG and requires further study.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据